Hospital Quironsalud Marbella
- Address
- lock Available on a paid plan
Respiratory Tract Diseases
The department is advancing research on asthma, chronic obstructive pulmonary disease, and idiopathic pulmonary fibrosis to improve patient outcomes and reduce severe cardiopulmonary events.
- Evaluation of triple inhaler therapy versus dual bronchodilator regimens
- Safety and tolerability of new propellant inhalers for asthma management
- Biologic treatment efficacy in eosinophilic and severe uncontrolled asthma
- Pre‑exposure prophylaxis with monoclonal antibodies against COVID‑19 variants
Hospital Quironsalud Marbella supports these studies with a dedicated team of respiratory specialists.
Digestive System Diseases
Research efforts focus on heartburn and reflux, evaluating novel therapeutic options and their safety profiles, especially in vulnerable populations.
- Safety assessment of almagate in pregnant women with reflux symptoms
- Monitoring perinatal outcomes associated with antacid therapy
- Comparative effectiveness of standard versus new acid‑suppressive agents
The site collaborates with gastroenterology experts to ensure comprehensive care for patients experiencing digestive discomfort.
Stomatognathic Diseases
Studies address conditions affecting the oral and maxillofacial region, linking gastro‑esophageal issues to oral health and exploring therapeutic interventions.
- Impact of chronic reflux on oral mucosa and dental health
- Evaluation of protective agents for stomatognathic tissue integrity
- Integration of dental assessments within respiratory and digestive trials
Multidisciplinary coordination at Hospital Quironsalud Marbella enhances the understanding of stomatognathic disease mechanisms.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 therapeutic areas and 15 of 20 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
- 1AstraZeneca AB1active
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB4trials
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 567 other sites in Spain
Therapeutic Area Benchmark — Spain
Select a therapeutic area to compare against other sites in Spain.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Spain
Market Share
Country: Spain
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Hospital Quironsalud Marbella
lock Showing 1 of 11 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A pivotal, multicentre, randomised, open-label, parallel-group trial on contraceptive efficacy, safety and tolerability of LVDS (Levonorgestrel Vaginal Delivery System) during 9 cycles in comparison with Desogestrel tablets 0.075 mg. | Chemo Research S.L. | Phase III | Not Recruiting | Jul 2023 | Mar 2025 |
IMP list
lock Showing 1 of 20 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Budesonide | 3 | Unknown | 2021-04-29 | 2025-04-29 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.